NervGen Pharma Corp.

📍 Vancouver, Canada🗓 Founded 2018👥 17 employees💰 Last funded Oct 2023
Biotechnology Research🌐 nervgen.com
Website LinkedIn
NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing innovative treatments for nervous system damage, due to injury or disease. NervGen’s lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin. NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory. NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Canada
1
Frequently asked questions
Who invested in NervGen Pharma Corp.?
NervGen Pharma Corp. has 1 investors on record on gritt.io, 1 mid-stage.
When did NervGen Pharma Corp. last raise funding?
The most recent investment in NervGen Pharma Corp. recorded on gritt.io was in October 2023.
When was NervGen Pharma Corp. founded?
NervGen Pharma Corp. was founded in 2018.
What industry is NervGen Pharma Corp. in?
NervGen Pharma Corp. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is NervGen Pharma Corp. based?
NervGen Pharma Corp. is headquartered in Vancouver, Canada.